Compare TAOP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | SNGX |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 12.0M |
| IPO Year | 2012 | 2006 |
| Metric | TAOP | SNGX |
|---|---|---|
| Price | $1.30 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.8K | ★ 109.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $119,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.14 | $1.02 |
| 52 Week High | $8.78 | $6.23 |
| Indicator | TAOP | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 52.34 |
| Support Level | $1.21 | $1.19 |
| Resistance Level | $1.59 | $1.22 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 19.44 | 86.67 |
Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).